LivaNova (NASDAQ:LIVN) Price Target Cut to $70.00 by Analysts at Mizuho

LivaNova (NASDAQ:LIVN) had its price target reduced by Mizuho from $80.00 to $70.00 in a research note published on Thursday, Benzinga reports. They currently have an outperform rating on the stock.

LIVN has been the topic of a number of other research reports. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Robert W. Baird upped their price objective on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research report on Thursday. The Goldman Sachs Group initiated coverage on LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective for the company. Finally, Stifel Nicolaus raised their price target on LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, LivaNova currently has an average rating of “Buy” and an average target price of $69.17.

LivaNova Stock Performance

NASDAQ LIVN opened at $51.13 on Thursday. The firm has a market cap of $2.78 billion, a P/E ratio of 121.74 and a beta of 1.01. The company has a quick ratio of 2.94, a current ratio of 3.37 and a debt-to-equity ratio of 0.49. The business’s 50-day moving average price is $51.13 and its 200 day moving average price is $53.12. LivaNova has a 52-week low of $42.75 and a 52-week high of $64.47.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.15. The firm had revenue of $318.60 million during the quarter, compared to the consensus estimate of $305.05 million. LivaNova had a return on equity of 13.81% and a net margin of 1.91%. On average, equities research analysts expect that LivaNova will post 2.58 earnings per share for the current year.

Institutional Trading of LivaNova

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its stake in LivaNova by 88.6% in the 1st quarter. BNP Paribas Financial Markets now owns 42,121 shares of the company’s stock worth $2,356,000 after buying an additional 19,783 shares during the last quarter. Driehaus Capital Management LLC boosted its stake in LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock worth $29,824,000 after buying an additional 213,749 shares during the last quarter. Perceptive Advisors LLC boosted its stake in LivaNova by 48.5% in the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock worth $24,340,000 after buying an additional 145,000 shares during the last quarter. Great Lakes Advisors LLC acquired a new stake in LivaNova in the 2nd quarter worth about $16,614,000. Finally, Quantbot Technologies LP acquired a new stake in LivaNova in the 1st quarter worth about $994,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.